login
  Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

Convergent procedure building support for interdisciplinary approach to atrial fibrillation


Tuesday, 05 Jun 2012 15:37
Borut Gersak
Borut Gersak


nContact has announced that an article was recently published in the Journal of Cardiovascular Electrophysiology chronicles the development of an new interdisciplinary approach for the treatment of atrial fibrillation, the convergent procedure, and illustrates the strong success of the site’s programme. Outcomes were determined by the most stringent methodology, 24-hour loop recorders, which demonstrated unparalleled success in this patient cohort. Physician reaction to the paper has been positive.


Lead author of the paper, Borut Gersak, chief of Cardiac Surgery, University Medical Center, Ljubljana, Slovenia, said: “This paper may be reviewed in hindsight as a pivotal paper in determining the true standard for success of an ablation procedure. The paper documents the evolution of a closed chest, truly minimally invasive interdisciplinary procedure, the Convergent Procedure, its early challenges and lessons learned, the protocols developed to improve and insure clinical safety, and the successful patient experience as monitored by a continuous loop recorder, Medtronic’s Reveal XT. The convergent procedure has proven itself under today’s most stringent monitoring standards, and sets a new and higher standard for clinical and patient outcome success.”

Kenneth Civello, cardiac electrophysiologist, Our Lady Of The Lake Regional Medical Center, Baton Rouge, Louisiana, USA, said: “The data is impressive, and the results are consistent with results we have obtained utilizing the Convergent Procedure in our hospital, and abstracts presented at Boston AF Symposium and the Heart Rhythm Society Scientific Sessions (HRS). This is important because the procedure can be standardised to obtain consistent results among a variety of sites. The results with patients in sinus rhythm off anti-arrhythmic drugs (AADs) of 74% are even more impressive because 94% of the patients were persistent or long standing persistent patients. HRS defines catheter outcome success as ’freedom from AF and off AADs at 40%’ for persistent patients and 30% for long standing persistent patients.”

Paul Mounsey, chief of Electrophysiology, University of North Carolina Hospital, Chapel Hill, North Carolina, USA, said: “This is an important paper because the Convergent Procedure addresses atrial fibrillation in a scientific manner by addressing both endocardial and epicardial substrates in a comprehensive anatomic approach. Its success can be related back to the large body of literature on lesion patterns, lesion completeness, substrate activation, anatomical remodeling, atrial stretch, and atrial function. This is not a potential magical silver bullet, but rather the use of an increasingly relevant and rapidly growing ablation technology to augment existing strategies.”

 




Add New Comment

Most popular


Abbott to acquire Topera and Advanced Cardiac Therapeutics
Wednesday, 29 Oct 2014
Abbott enters the catheter-based electrophysiology market with the announcement of an agreement to purchase Topera and the securement of the rights to purchase Advanced Cardiac Therapeutics (ACT). B... Abbott to acquire Topera and Advanced Cardiac Therapeutics

Long-term overtreatment with antiplatelet/anticoagulant therapy may increase the risk of dementia in AF patients
Friday, 21 Nov 2014
Atrial fibrillation patients who are receiving a combination of antiplatelet and anticoagulant therapy and are over treated with warfarin may be at an increased risk of dementia, according to a ... Long-term overtreatment with antiplatelet/anticoagulant therapy may increase the risk of dementia in AF patients

FDA approves Cardinal Health MynxGrip Vascular Closure Device for venous indication
Saturday, 08 Nov 2014
Cardinal Health has announced that its MynxGrip Vascular Closure Device recently received Food and Drug Administration (FDA) approval for use to close femoral veins. The MynxGrip device is now ... FDA approves Cardinal Health MynxGrip Vascular Closure Device for venous indication

Features


The challenge of left ventricular lead placement: What is the role of quadripolar leads?
Tuesday, 16 Dec 2014
George H Crossley (Nashville, USA) writes on the role of quadripolar leads in cardiac resynchronisation therapy to treat heart failure patients. The challenge of left ventricular lead placement: What is the role of quadripolar leads?

Highlights from ISCAT 2014
Thursday, 20 Nov 2014
Michel Haïssaguerre and Etienne M Aliot, chairmen of the International Symposium on Catheter Ablation Techniques (ISCAT; 15–17 October 2014, Paris, France), discuss the highlights of this year’s ... Highlights from ISCAT 2014

Profiles


Massimo Santini
Friday, 10 Oct 2014
Massimo Santini performed the first fulguration of the atrioventricular node of resistant ... Massimo Santini

Nick Linker
Monday, 14 Jul 2014
Nick Linker is president-elect of the British Heart Rhythm Society (BHRS) and programme director of ... Nick Linker

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions